Inhibikase Therapeutics to present at the International Congress on Parkinson’s Disease and Movement Disorders

[ad_1]

BOSTON and ATLANTE, September 8, 2022 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor treatments to modify the course of Parkinson’s disease, related disorders Parkinson’s and other Abelson tyrosine kinase diseases, today announced that Milton Werner, Ph.D., President and CEO of Inhibikase, will present at the International Congress on Parkinson’s Disease and Movement Disorders. The congress is held at Madrid, Spain and practically between September 15-18, 2022.

Presentation details:

Title of abstract: IkT-148009 as a potential disease-modifying therapy in PD
Abstract number: 789
Session: GPT 6, Parkinson’s disease: clinical trials
Presentation date and time: September 16, 2022, 1:00 p.m. – 3:00 p.m. CEST / 7:00 a.m. – 09:00. is
Location: France Gallery, Madrid Marriott Auditorium Hotel and Conference Center

About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing treatments for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline focuses primarily on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease internally and externally. of the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline targets disorders of the brain and gastrointestinal tract related to Parkinson’s disease, orphan indications related to Parkinson’s disease such as multiple system atrophy and drug delivery technologies for kinase inhibitors such as as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the company says will provide a better patient experience with fewer dosage-related side effects. The company’s RAMP™ medicinal chemistry program has identified a number of compounds complementary to IkT-148009 that have potential application to other cognitive and motor brain diseases. Inhibikase is headquartered in Atlanta, Georgia with offices at Boston, MA.

Social Media Disclaimer
Investors and others should note that the Company announces important financial information to investors through its investor relations website, press releases, SEC filings, public conference calls and webcasts. The Company also intends to use TwitterFacebook, LinkedIn, and YouTube as a means of disclosing information about the Company, its services, and other matters and to comply with its disclosure obligations under the FD Regulations.

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes”, “expects”, “may”, “will”, “should”, “anticipates”, “plans” or similar expressions or the negative form of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. These statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the documents Inhibikase’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, including under the heading “Risk Factors”. Any forward-looking statements in this release speak only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable securities laws.

contacts:

Company Contact:
Milton H. Wernerdoctorate
President and CEO
678-392-3419
[email protected]

Investor Relations:
Alex Lobo
SternIR, Inc.
[email protected]

SOURCE Inhibikase Therapeutics, Inc.


[ad_2]
Source link

Comments are closed.